Promacta Copay Card & Patient Assistance Programs 2025: Complete

If you’ve been prescribed Promacta (eltrombopag) for thrombocytopenia or aplastic anemia, you may be concerned about the cost of this specialty medication. The good news is that several financial assistance options exist, including Promacta copay card programs, eltrombopag copay assistance, and eltrombopag patient assistance programs that can significantly reduce your out-of-pocket expenses.

At QuickRx Specialty Pharmacy, we help patients navigate the complex landscape of Promacta and eltrombopag copay assistance options. Whether you have private insurance, Medicare, or no insurance at all, our team can guide you to the right programs and handle the enrollment process on your behalf.

This comprehensive guide covers everything you need to know about Promacta copay cards, eltrombopag patient assistance programs, generic eltrombopag availability, and alternative treatment options.

What Is Promacta?

Promacta (eltrombopag) is an oral thrombopoietin receptor agonist manufactured by Novartis Pharmaceuticals. It works by stimulating the bone marrow to produce more platelets, helping patients with dangerously low platelet counts.

The FDA first approved Promacta in November 2008, and it has since received approval for multiple indications:

FDA-Approved Uses for Promacta:

• Chronic immune thrombocytopenia (ITP) – For adults and children 1 year and older who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy
• Thrombocytopenia in chronic hepatitis C – To allow initiation and maintenance of interferon-based therapy in adults
• Severe aplastic anemia (SAA) – In combination with standard immunosuppressive therapy for newly diagnosed patients, or alone for patients who have had insufficient response to immunosuppressive therapy

Promacta is available in multiple strengths: 12.5 mg, 25 mg, 50 mg, and 75 mg tablets, as well as an oral suspension for patients who have difficulty swallowing tablets. Outside the United States, Promacta is marketed under the brand name Revolade.

Promacta Copay Card & Eltrombopag Copay Assistance Programs

For patients with private insurance, a Promacta copay card or eltrombopag copay card can significantly reduce monthly medication costs. Novartis offers several financial assistance options through their oncology support programs.

Novartis Oncology Universal Co-pay Program

The Novartis Oncology Universal Co-pay Program may help eligible patients with private insurance pay for their Promacta prescription:

• How it works: Eligible patients may pay a reduced amount per month, with Novartis covering the remaining copay costs
• Annual assistance limits apply: The program has a combined annual limit per product
• Eligibility: Available to patients with private insurance who meet program criteria
• Not available for: Patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs

To learn more about the Novartis copay program or check eligibility, patients can visit the Novartis website or call their support line. However, navigating these programs can be confusing—that’s where QuickRx can help.

Other Eltrombopag Copay Assistance Options

Beyond manufacturer programs, additional eltrombopag copay assistance may be available through:

• Patient Access Network (PAN) Foundation – Provides copay assistance for eligible patients
• HealthWell Foundation – Offers copay support for qualifying patients
• Patient Advocate Foundation Co-Pay Relief Program – Helps reduce financial distress from medication costs

Eligibility requirements vary by program. Contact QuickRx Specialty Pharmacy to explore which programs you may qualify for.

Promacta & Eltrombopag Patient Assistance Programs

For patients who are uninsured or cannot afford their medication even with insurance, the Promacta patient assistance program and eltrombopag patient assistance program through the Novartis Patient Assistance Foundation may provide medication at no cost.

Novartis Patient Assistance Foundation (NPAF)

The Novartis Patient Assistance Foundation provides Novartis medications free of charge to eligible patients who meet specific criteria:

• No insurance coverage: Patients without prescription drug coverage may qualify
• Limited coverage: Patients whose insurance doesn’t adequately cover the medication
• Income requirements: Must meet household income guidelines that vary by product and household size
• U.S. residents: Must be a resident of the United States

Patient Assistance Now Oncology (PANO)

Novartis offers Patient Assistance Now Oncology (PANO) as a central resource for accessing their oncology patient support programs. Through PANO, patients receive:

• One-on-one guidance from a dedicated case manager
• Help determining which programs they’re eligible for
• Referrals to other services and independent charitable foundations
• Assistance with enrollment paperwork

For more information about the Promacta patient assistance program, patients can call 1-800-277-2254 or work with QuickRx to navigate the application process.

Is There a Generic Version of Promacta (Eltrombopag)?

Yes, generic eltrombopag is now available in the United States.

First, let’s clarify: eltrombopag is the generic (chemical) name of the medication, while Promacta is the brand name sold by Novartis. When people ask “is there a generic for Promacta,” they’re asking whether other manufacturers make eltrombopag — and the answer is yes.

The FDA has approved generic eltrombopag from manufacturers other than Novartis, providing patients with additional options that may offer cost savings:

Generic Eltrombopag Approval Timeline:

• November 29, 2023: Teva Pharmaceuticals received FDA approval for Alvaiz (eltrombopag choline) tablets in 9 mg, 18 mg, 36 mg, and 54 mg strengths
• April 18, 2024: Annora Pharma received FDA approval for generic eltrombopag oral suspension (12.5 mg and 25 mg packets)
• January 17, 2025: Hetero Labs received FDA approval for generic eltrombopag

Important Notes About Generic Eltrombopag:

While generic eltrombopag options exist, there are some important considerations:

• Alvaiz uses a different salt form: Alvaiz contains eltrombopag choline rather than eltrombopag olamine (used in brand Promacta), resulting in different tablet strengths
• Availability may vary: FDA approval doesn’t guarantee immediate pharmacy availability; patents and exclusivity rights may affect when generics reach the market
• Insurance coverage varies: Your insurance plan may prefer brand Promacta or generic eltrombopag depending on their formulary
• Same active ingredient: All versions contain eltrombopag and work the same way in your body

Contact QuickRx to discuss whether generic eltrombopag is available and appropriate for your situation.

Promacta Alternatives

If Promacta isn’t the right fit for you—whether due to cost, side effects, or other factors—several Promacta alternatives may be available depending on your condition:

Alternative Thrombopoietin Receptor Agonists:

• Nplate (romiplostim) – An injectable TPO receptor agonist manufactured by Amgen; approved for chronic ITP in adults and children
• Doptelet (avatrombopag) – An oral TPO receptor agonist approved for thrombocytopenia in patients with chronic liver disease and chronic ITP

Key Differences:

• Administration: Promacta and Doptelet are oral medications; Nplate requires subcutaneous injection
• Dosing frequency: Varies by medication and indication
• Food interactions: Promacta must be taken on an empty stomach and cannot be taken with calcium-rich foods; Doptelet is taken with food

Only your healthcare provider can determine which treatment is most appropriate for your specific condition. If cost is a concern, QuickRx can help explore copay assistance options for whichever medication is prescribed.

How QuickRx Helps You Access Promacta

At QuickRx Specialty Pharmacy, we specialize in helping patients access specialty medications like Promacta. Our experienced team understands the challenges of affording these treatments—and we’re here to help every step of the way.

Our Team Will:

• Review your insurance coverage and identify your best options
• Help you enroll in Promacta copay card programs if you have private insurance
• Guide you through Promacta patient assistance program applications if you’re uninsured or underinsured
• Explore foundation assistance and other financial support options
• Handle enrollment paperwork and coordination on your behalf
• Arrange convenient home delivery of your medication
• Provide ongoing support and refill reminders

Getting started is easy: Call us at (917) 830-2525 or toll-free at (800) 496-6111, or fill out our online form. A pharmacy liaison will personally review your situation within one business day.

Learn more about our Promacta copay assistance services and how we can help make your treatment more affordable.

Frequently Asked Questions About Promacta & Eltrombopag

References

1. U.S. Food and Drug Administration. Promacta (eltrombopag) Approval History. https://www.drugs.com/history/promacta.html. Accessed December 2025.
2. Novartis Pharmaceuticals. Promacta Prescribing Information. https://www.novartis.com/
3. Novartis Patient Assistance Foundation. https://pap.novartis.com/. Accessed December 2025.
4. Drugs.com. Generic Promacta Availability. https://www.drugs.com/availability/generic-promacta.html. Accessed December 2025.
5. DrugPatentWatch. Promacta Patent and Generic Information. https://www.drugpatentwatch.com/. Accessed December 2025.